Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$11.59 USD
+1.12 (10.70%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.50 -0.09 (-0.78%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Dyne Therapeutics, Inc. has a market cap of $1.49B, which represents its share price of $10.47 multiplied by its outstanding shares number of 142.26M. As a small-cap company, DYN's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
DYN 11.59 +1.12(10.70%)
Will DYN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DYN
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
Other News for DYN
Dyne Therapeutics trading resumes
Dyne Therapeutics trading halted, volatility trading pause
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.00 | DYN Stock News
Dyne Therapeutics price target lowered by $21 at Oppenheimer, here's why
Dyne Therapeutics (DYN) Gains FDA Breakthrough Status for DYNE-251